Merck KGaA Shares Plummet After Stifel Downgrades to Sell Rating

lunes, 7 de julio de 2025, 2:43 am ET1 min de lectura
MRK--

Merck KGaA shares dropped 2.5% in pre-market trading after Stifel analyst Dylan Van Haaften lowered his price target from €153 to €100 and changed his rating from "Buy" to "Sell". Van Haaften expressed concerns about the potential early patent expiration for the MS drug Mavenclad, leading him to significantly lower his estimates for the 2026 fiscal year.

Merck KGaA Shares Plummet After Stifel Downgrades to Sell Rating

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios